Artiva Biotherapeutics, Inc.
ARTVNasdaq
$9.76
↑ +8.0%Jul 17 close · end-of-day
Price
1Y↑ +310.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$240.9M
Enterprise Value
$154.1M
P/E
—
P/S
—
P/B
2.7
EV/EBITDA
—
PEG
—
FCF Yield
-33.3%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$87.1M
Free Cash Flow (TTM)
-$80.2M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-99.1%
ROIC
-6829.5%
Debt / Equity
—
Net Cash
$86.8M
Return 1Y
+276.8%
Company profile
We are a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our principal executive offices are located at 5505 Morehouse Drive, Suite 100, San Diego, California.
- CEO
- Fred Aslan
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- California
- Website
- www.artivabio.com
Management & directors
- Aslan FredChief Executive Officer
- Banerjee SubhashisChief Medical Officer
- Bush JenniferCOO, CLO, Secy, Compliance Off
- Horan ChristopherChief Tech Operations Officer
- Raymon HeatherSVP, Research and Development
- Miralles Gines DiegoPresident & Head of R&D
- Huston Thad AllenChief Financial Officer
- Krishnamohan NehaChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
ARTV Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.95↑ +14.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $33.5M | $251,000.00 | $0.00 |
| Gross profit | — | — | — |
| Operating income | -$30.7M | -$67.3M | -$89.8M |
| Net income | -$28.7M | -$65.4M | -$83.9M |
| Diluted EPS | -$35.78 | -$5.81 | -$3.43 |
| Operating cash flow | -$47.4M | -$55.0M | -$76.8M |
| Free cash flow | -$50.7M | -$55.7M | -$79.3M |
| Gross margin | — | — | — |
| Operating margin | -91.6% | -26805.6% | — |
| Net margin | -85.8% | -26045.0% | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$16.2M | -$18.3M | -$18.3M | -$22.2M | -$22.8M | -$22.9M | -$21.9M | -$24.4M |
| Net income | -$17.8M | -$17.5M | -$16.1M | -$20.3M | -$21.3M | -$21.5M | -$20.8M | -$23.5M |
| Diluted EPS | -$22.00 | -$0.92 | $34.35 | -$0.83 | -$0.87 | -$0.88 | -$0.85 | -$0.95 |
| Operating cash flow | -$13.7M | -$11.6M | -$14.7M | -$19.8M | -$23.0M | -$19.2M | -$14.7M | -$20.9M |
| Free cash flow | -$14.1M | -$11.7M | -$14.7M | -$20.4M | -$24.0M | -$19.8M | -$15.1M | -$21.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-13 | RA CAPITAL MANAGEMENT, LLC | Buy | 6,552 | $8.94 | $58,574.88 | filing |
| 2026-07-10 | RA CAPITAL MANAGEMENT, LLC | Buy | 15,102 | $8.97 | $135,464.94 | filing |
| 2026-06-26 | RA CAPITAL MANAGEMENT, LLC | Buy | 1,876 | $8.98 | $16,846.48 | filing |
| 2026-06-25 | RA CAPITAL MANAGEMENT, LLC | Buy | 31,000 | $8.88 | $275,280.00 | filing |
| 2026-06-16 | RA CAPITAL MANAGEMENT, LLC | Buy | 124,893 | $8.89 | $1.1M | filing |
| 2026-06-15 | RA CAPITAL MANAGEMENT, LLC | Buy | 15,414 | $8.99 | $138,571.86 | filing |
| 2026-06-12 | RA CAPITAL MANAGEMENT, LLC | Buy | 391,019 | $8.57 | $3.4M | filing |
| 2026-06-11 | RA CAPITAL MANAGEMENT, LLC | Buy | 548,580 | $7.91 | $4.3M | filing |
| 2026-06-10 | RA CAPITAL MANAGEMENT, LLC | Buy | 103 | $7.00 | $721.00 | filing |
| 2026-06-09 | RA CAPITAL MANAGEMENT, LLC | Buy | 479,039 | $6.91 | $3.3M | filing |
| 2026-05-19 | Aslan Fred· Chief Executive Officer | Sale | 27,116 | $9.01 | $244,252.79 | filing |
| 2026-05-19 | Bush Jennifer· COO, CLO, Compliance Officer | Sale | 8,790 | $9.01 | $79,178.56 | filing |
| 2026-05-19 | Banerjee Subhashis· Chief Medical Officer | Sale | 7,037 | $9.01 | $63,386.48 | filing |
| 2026-05-19 | Horan Christopher· Chief Tech Operations Officer | Sale | 7,002 | $9.01 | $63,072.62 | filing |
| 2026-05-19 | Raymon Heather· SVP, Research and Development | Sale | 3,095 | $9.01 | $27,879.14 | filing |
| 2026-05-18 | Miralles Gines Diego· President & Head of R&D | Award | 77,500 | $0.00 | $0.00 | filing |
| 2026-05-11 | RA CAPITAL MANAGEMENT, LLC | Buy | 6,510,416 | $11.52 | $75.0M | filing |
| 2026-05-11 | GC Corp. | Buy | 1,085,069 | $11.52 | $12.5M | filing |
| 2026-05-11 | GC Corp. | Buy | 347,222 | $11.52 | $4.0M | filing |
| 2026-03-10 | Huston Thad Allen· Chief Financial Officer | Award | 220,000 | $0.00 | $0.00 | filing |
| 2026-02-15 | Aslan Fred· President and CEO | Tax withholding | 14,600 | $4.00 | $58,400.00 | filing |
| 2026-02-15 | Bush Jennifer· COO, CLO, Secy, Compliance Off | Tax withholding | 3,515 | $4.00 | $14,060.00 | filing |
| 2026-02-15 | Horan Christopher· Chief Tech Operations Officer | Tax withholding | 2,187 | $4.00 | $8,748.00 | filing |
| 2026-02-15 | Raymon Heather· SVP, Research and Development | Tax withholding | 1,521 | $4.00 | $6,084.00 | filing |
| 2026-02-15 | Bush Jennifer· COO, CLO, Secy, Compliance Off | Award | 117,300 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.